Navigation Links
Blanchette Rockefeller Neurosciences Institute and Inverness Medical Innovations to Develop Commercial Test to Detect Early Alzheimer's Disease

MORGANTOWN, W.Va., May 27 /PRNewswire-USNewswire/ -- The Blanchette Rockefeller Neurosciences Institute (BRNI) and Inverness Medical Innovations, Inc. (Inverness, NYSE: IMA) of Waltham, Massachusetts, a global leader in rapid diagnostics and health management, announced today that they will work together to further develop and commercialize a diagnostic test for Alzheimer's disease first discovered by scientists at BRNI.

The BRNI test, once fully commercialized, could dramatically change the time and way that the disease is treated. The agreement also marks the first major global private sector deal involving BRNI technology and science. Under the terms of the arrangement, Inverness will fund the development efforts to be conducted by BRNI over an initial three year period. Inverness has also obtained an option which, if exercised, will provide Inverness with certain rights to the technology developed for use in the diagnosis, prognosis and monitoring of Alzheimer's disease.

"We are very pleased to be working with the world-class memory institute at BRNI, and share in their commitment to advance this test for Alzheimer's disease," said Ron Zwanziger, CEO of Inverness. "This is an exciting opportunity for Inverness to enhance the lives of patients with chronic disease and continues our commitment to rapidly deploy diagnostics and develop new treatments for devastating diseases such as Alzheimer's."

Affecting over 5 million Americans, Alzheimer's disease (AD) has no recognized cure and is difficult to diagnose. In fact, doctors can only definitely diagnose the illness at autopsy and there is currently no approved biochemical test to diagnose it. Finding a cure for AD is one of the central missions of the Blanchette Rockefeller Neurosciences Institute. In 2005, the cost to Medicare for care of beneficiaries with AD and other dementias was $91 billion and the cost to state and federal Medicaid for nursing home care for people with AD and other dementias was $21 billion. Dementia currently afflicts over 29 million people worldwide, and the annual global costs of dementia are estimated to amount to $315 billion.

"It is still challenging to accurately diagnose Alzheimer's disease, but I believe we are on the path to realizing a test that will take the guess work out of proper treatment," said Dr. Daniel Alkon, Scientific Director of BRNI. "An accurate early test will allow physicians to treat patients sooner and more effectively before symptoms intensify and the disease rapidly escalates."

The only non-profit independent institution in the world dedicated to the study of human memory and memory disorders, BRNI first discovered the biomarker test's potential in 2006. By testing for signs of AD-related inflammation in skin cells called fibroblasts, the BRNI team located a biomarker for the disease that can be tested without the invasive procedures previously required, such as a lumbar tap. The key molecular targets that the BRNI biomarker determines reflect PKC signaling which appears to be compromised very early on during AD and probably well before the onset of clinical symptoms. These pathways could also be a focus for drug therapy.

"An early diagnosis could prevent countless patients from suffering through this devastating disease," said William Singer, President of BRNI's Board of Directors. "This partnership will ensure that expanded clinical trials occur quickly which will be a major leap in bringing a proven Alzheimer's disease diagnostic to the public."

A recent study has been conducted with more than 300 patients in 15 hospitals, and autopsy-confirmations have been obtained from 42 patients. Based on autopsy validation, the BRNI biomarker had a 98 percent level of accuracy in detecting AD. This accuracy was also achieved for the early diagnosis of AD (within the first four years of memory loss symptoms). Clinical diagnosis, as confirmed by autopsy, is considerably less accurate in diagnosing AD at such early stages. The BRNI biomarker showed high accuracy when tested with human skin cells from a tissue bank, as well as for samples obtained from the patients with autopsy-confirmed diagnoses.

"Ultimately, the goal of the Blanchette Rockefeller Neuroscience Institute (BRNI) is to cure Alzheimer's disease, and the path to a cure begins with detecting the disease early," said Senator Jay Rockefeller (D-WV), who founded BRNI in honor of his mother. "I applaud the Inverness-BRNI partnership for advancing this research, and I'm deeply proud of the work that goes on every day in West Virginia at BRNI to get us closer to a greater understanding of the disease and a cure."

About BRNI

BRNI is the world's only non-profit institute dedicated to the study of both human memory and diseases of memory. Its primary mission is to accelerate the transfer of neurological discoveries from the lab to the doctor's office where it can benefit patients who suffer from neurological and psychiatric diseases.

BRNI is operated in alliance with West Virginia University in Morgantown as well as in collaboration with other academic institutions such as Johns Hopkins University. West Virginia Senator Jay Rockefeller founded the Institute in memory of his mother, Blanchette Hooker Rockefeller, who died of Alzheimer's disease.

About Inverness Medical Innovations, Inc.

By developing new capabilities in near-patient diagnosis, monitoring and health management, Inverness Medical Innovations, Inc. (NYSE: IMA) enables individuals to take charge of improving their health and quality of life. A global leader in rapid point-of-care diagnostics, Inverness' products, as well as its new product development efforts, focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Inverness is headquartered in Waltham, Massachusetts.

SOURCE Blanchette Rockefeller Neurosciences Institute
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
2. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
3. Intellect Neurosciences, Inc. and Medical Research Council Technology (U.K.) Reach Important Milestone in Generating an Alzheimers Therapeutic Antibody
4. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
5. Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program
6. Intellect Neurosciences, Inc. and CHDI, Inc. Enter Into Compound Testing Agreement to Evaluate OXIGON(TM) as a Potential Treatment for Huntington Disease
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. Feldenkrais(R) Movement Institute Announces Simple Non-Surgical Solutions for Jaw and Facial Pain (TMJ)
9. Lions Eye Institute for Transplant & Research, Inc. Launches Multi-Million Dollar, State-of-the-Art Research Institute that Will Advance the Study of Blinding Eye Diseases
10. Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia
11. Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference
Post Your Comments:
(Date:11/25/2015)... -- Allergan plc (NYSE: AGN ), a ... start-up  biotechnology company focused on the development of ... by the F-Prime Biomedical Research Initiative (FBRI), today ... collaboration to support the discovery and development of ... Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... Ohio , Nov. 25, 2015 ... handle hazardous drug preparations (e.g. pharmacists, pharmacy technicians, ... and veterinary technicians). The chapter also covers all ... drugs (e.g., pharmacies, hospitals, other healthcare institutions, patient ... --> --> ...
(Date:11/25/2015)... Asia -based venture ... and the New Investors will make a direct equity ... private placement. The financing will help IOPtima to continue ... in the treatment of glaucoma, as well as to ... system with the U.S. Food and Drug Administration, commencing ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... all, Water For Empowerment ™ attracts volunteers together who want to combine ... empowering women as key stakeholders in the process. The non-profit launched its first ...
(Date:11/25/2015)... Cokato, MN (PRWEB) , ... November 25, 2015 ... ... manufacturer, launched offering factory direct sauna parts and accessories. , Sauna accessories ... representative of the bather’s style and personality. From basic styles for the purist ...
(Date:11/25/2015)... ... , ... For the first time, Vitalalert is donating half of its earnings ... partnership between the two groups began in 2014 with Vitalalert pledging a portion of ... was founded in 1954 and is an international Christian-based health organization whose mission is ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... , ... November 25, 2015 , ... Smiles by ... TMJ Disorder, Bruxism, and moderate facial wrinkling. While many patients are aware of the ... the great success Botox® delivers to those suffering with discomfort, soreness, and pain as ...
Breaking Medicine News(10 mins):